Information and Acceptability of Biosimilars

  • End date
    Nov 26, 2023
  • participants needed
  • sponsor
    University Hospital, Montpellier
Updated on 26 November 2021
tumor necrosis factor
rheumatic diseases
rheumatoid arthritis


Patients with rheumatoid arthritis or spondyloarthritis, currently treated or about to be started with anti-TNF original drug adalimumab or etanercept will be included and randomized to either " information leaflet only " or " information leaflet + nurse information " arms, just before they see their rheumatologist for periodic assessment of disease and treatment.

Patients from the " information leaflet only " arm will be distributed individually a dedicated leaflet with written generic informations about the use of biosimilars in rheumatic diseases (individual and societal advantages, pharmaceutical development, scientific efficacy and safety results).

Patients from the " " information leaflet + nurse information " arm will be delivered the same leaflet, and additionally offered to have a dedicated individual interview with a specialist nurse, who will orally discuss informations about biosimilars based on a standardized talk, completed by answers to any questions by the patient.

The rheumatologist will then propose, unless inappropriate based on clinical evaluation of the patient, a change in the treatment of patients from the original drug to the corresponding biosimilar.

The primary outcome will be the observed proportions of patients actually receiving the biosimilar drug at the 6-months follow-up visit in the 2 compared arms.

Secondary outcomes will be average time spent by the nurse to adequatley inform the patient, the proportion of patients from the intervention arm who have actually asked for the nurse information interview, and the reasons for refusal of biosimilars, when appropriate.

Condition Spondyloarthropathy, Psoriasis and Psoriatic Disorders, Arthritis and Arthritic Pain (Pediatric), Arthritis and Arthritic Pain, Spondylarthritis, Psoriasis, spondyloarthritis, Psoriatic Arthritis, PSORIATIC ARTHRITIS, Arthritis, Rheumatoid Arthritis (Pediatric), Rheumatoid Arthritis
Treatment Generic information leaflet, Individual information by nurse on biosimilars
Clinical Study IdentifierNCT04321291
SponsorUniversity Hospital, Montpellier
Last Modified on26 November 2021


Yes No Not Sure

Inclusion Criteria

Age 18 and over (no upper age limit)
All adult patients seen in rheumatology consultation at the Montpellier Hospital
With inflammatory rheumatism (rheumatoid arthritis or spondyloarthritis)
Treated (or in the process of being treated at the end of the consultation) by etanercept or adalimumab
In whom the biomedical treatment already used should in principle be renewed without modification (patient deemed good responder and well tolerant of the treatment)
Or where biomedical initiation has just been indicated during the consultation
Member of a social security scheme
Informed and written consent

Exclusion Criteria

Unable to understand information (not fluent in the French language, severe cognitive impairment, etc.)
Known intolerance to one of the proposed biosimilar excipients
Vulnerable persons: pregnant woman, minor patient, deprived of liberty, under guardianship or under curatorship
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note